The FDA has accepted to review Innovent Biologics Inc (OTC: IVBIY) and Eli Lilly and Co's (NYSE: LLY) marketing application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). It is the first U
Full Story >>
Vote
+10